Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by Ricky55on May 28, 2013 5:09pm
195 Views
Post# 21484261

It's confirmed now,time to buy!

It's confirmed now,time to buy!

Here is a small article coming from Louis James,Casey research
Subject: Casey Research update on NioGold

For me ,it's sound great! But i hope his strong buy at $0.10 never come.....................

C

NioGold Mining Corp.
Hm: Au
V.NOX, NOXGF.OB, www.niogold.com

Price

Share: C$0.16

MCap: C$17.1M

On: 5/23/13

History

Rec: C$0.345, 2/25/11

Loss: 53.6%

52-week: C$0.12-C$0.50

Shares

SO: 106.8 million

FD: 115.7 million

As of: 4/2013

Warrants

Nil

Options

Open: 8.9 million

C$0.20-C$0.43

Exp: 8/2013-9/2017

Cash

C$6 million working capital

Burn: C$400K/mo

As of: 4/2013

BUY FIRST TRANCHE NioGold is relatively well cashed up, among our early-stage explorers, and delivered some very solid drill results in early April, from the Marban block, including 4.47 g/t gold over 3.4 meters and 15.41 g/t gold over 2.8 meters. There's been no change in the JV arrangement with Aurizon yet (which is being taken over by Hecla, HL), so they are still paying for the work. We see this as a win-win, whatever the new owners decide to do: give it back 100%, or keep paying for the work to earn their first 50% of the project.

Given that the company has plenty of cash, other lottery tickets (projects) in the drum, a major partner paying for the work on its flagship, and is selling cheaper than it has in years, we'd buy a first tranche or average down if we were in at higher prices.

T1: Buy

T2: Buy if in at higher prices, or shoot for $0.14.

Srong Buy: $0.10 or less.

Louis James
Chief Metals & Mining Investment Strategist
Casey Research

<< Previous
Bullboard Posts
Next >>